Research On ESG Information Disclosure Of Listed Companies In Pharmaceutical Industry

ESG,comprising of the initials of three English words Environmental,Social and Governance,to begin with showed up within the Worldwide Compact discharged by the Joined together Countries in June 2004,and started from the negative affect of fast financial development on society and the environment.Beneath weight from partners,companies have made dynamic commitments on natural,social and corporate governance issues and begun to reveal ESG data in arrange to preserve the authenticity of their operations.With the consideration of A-shares in its Rising Markets List and Worldwide Benchmark File by worldwide file supplier Ming Sheng(MSCI)in June 2018,proclaiming the starting of China’s financial integration into the worldwide advancement prepare,it has too advanced A-share recorded companies to require the activity to reinforce ESG administration and data divulgence,so that their claim ESG execution has been ceaselessly progressed.However,according to the ESG rating released by MSCI in November 2019,my country’s listed companies as a whole are still 1-2 levels behind the emerging market index,and there is a clear gap with global best practices,and there is a lot of room for improvement.In particular,the pharmaceutical industry,which is related to life safety,is ahead of its global peers in terms of "product safety and quality",but slacks behind its worldwide peers in issues such as debasement,flimsiness,and carbon emanations.With the emergence of the new crown epidemic in 2020,the pharmaceutical sector of the A-share market has repeatedly seen rampant market conditions,but at the same time,negative ESG incidents have frequently erupted.In this great change,ESG performance has become one of the main measurement factors for the steady operation of the pharmaceutical industry,and it is pressing to constrain companies to move forward their ESG administration level through data divulgence prerequisites.Thus,this paper takes responsibility investment development situation is good,especially the new crown outbreak prompted human reflections on the old development model as the research background,relying on the triple bottom line,stakeholders and information asymmetry theory,using the method of literature,through contrast mainstream ESG rating system at home and abroad,using the analytic hierarchy process and fuzzy comprehensive evaluation ESG disclosure evaluation system construction of medical industry.Fosun Pharma,which won the "2020 Brilliant Emblem Grant for Social Obligation of Recorded Companies",was utilized as a case consider to confirm the appropriateness of the developed ESG disclosure assessment framework within the pharmaceutical industry.The comes about appear that the assessment framework is pertinent and will offer assistance pharmaceutical companies to progress their information of ESG as before long as conceivable,take after the worldwide bound together ESG standard,and take ESG revelation as a beginning point to advance the long-term maintainable advancement of the industry.